Core Viewpoint - The company Fangsheng Pharmaceutical (603998) held a product launch and investor reception event on December 21, discussing recent operations, research and development, and new product plans, highlighting the inclusion of its innovative traditional Chinese medicine "Yangxue Qufeng Zhitong Granules" in the 2025 National Medical Insurance Directory through recent negotiations [1] Group 1: Strategic Plans - The company plans to increase investment in innovative traditional Chinese medicine, aiming to accelerate the progress of its research pipeline over the next three years [1] - The company aims to create a product matrix with multiple products achieving annual sales of 300 to 500 million yuan [1] - For the newly included "Yangxue Qufeng Zhitong Granules," the company has set a market target for 2026 to cover over 500 public medical institutions and strives for its sales revenue to exceed that of its previous innovative product "Xuanqi Jiangu Pian" in its first year [1] Group 2: Research and Development - The company currently has a research pipeline for innovative traditional Chinese medicine covering multiple departments, with several projects such as "Yiqi Xiaoliu Granules" and "Ziying Granules" having received clinical trial approval [1] - The chemical drug research project "Indobufen Tablets" has obtained a drug registration certificate [1] Group 3: Financial Performance - In the first three quarters, the company achieved a net profit attributable to shareholders of 268 million yuan, representing a year-on-year increase of 17.60% [1] - The industrial hemp business of the company's wholly-owned subsidiary, Yunnan Fuya Biotechnology Co., Ltd., generated nearly 20 million yuan in revenue in the first three quarters of 2025, showing significant year-on-year growth, with expectations for annual revenue to exceed 30 million yuan for the first time [1]

Core Viewpoint - The company, TianKang (301263.SZ), has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration (NMPA) of China, indicating progress in its drug approval process [1]. Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1]. - The NMPA has reviewed the application according to Article 32 of the Administrative Licensing Law of the People's Republic of China and has decided to accept the application [1]. Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risks [1]. - The drug is intended for use in ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis formation, and it can also be used to prevent thrombosis during hemodialysis [1].

Core Viewpoint - The announcement highlights significant regulatory approvals for two pharmaceutical products from the company's subsidiaries, indicating progress in their product development pipeline and potential market expansion [1] Group 1: Regulatory Approvals - The company's wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received a drug registration certificate for Methimazole tablets from the National Medical Products Administration [1] - Another subsidiary, Anhui Tianenkang Pharmaceutical Co., Ltd., received an acceptance notice for the domestic production drug registration application for Indobufen tablets from the National Medical Products Administration [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Anhui Taienkang Pharmaceutical Co., Ltd., has received a notice of acceptance for the production registration application of Indobufen tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Indobufen tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risk [1] - The medication is indicated for ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - Indobufen tablets can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration, indicating progress in bringing this drug to market [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application [1] - The National Medical Products Administration has reviewed and accepted the application for Indobufen Tablets [1] Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce thrombotic risk [1] - The drug is intended for use in ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as for preventing thrombosis during hemodialysis [1]

Core Viewpoint - The company TianKang (301263.SZ) has received a notice of acceptance for the production registration application of Indobufen Tablets from the National Medical Products Administration of China, indicating progress in bringing this drug to market [1] Group 1: Company Developments - TianKang's wholly-owned subsidiary, Anhui TianKang Pharmaceutical Co., Ltd., has recently received the acceptance notice for the drug registration application for Indobufen Tablets [1] - The National Medical Products Administration has reviewed and accepted the application for the drug, which is a significant step towards its market launch [1] Group 2: Product Information - Indobufen Tablets are classified as platelet aggregation inhibitors, which work by reversibly inhibiting cyclooxygenase and various inducers to reduce the risk of thrombosis [1] - The drug is intended for use in ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, as well as for preventing thrombosis during hemodialysis [1]

Core Viewpoint - 石四药集团 has received production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1: Company Developments - 石四药集团's stock rose nearly 3%, currently up 2.68% at HKD 3.06, with a trading volume of HKD 16.01 million [1] - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1] Group 2: Market Insights - Indobufene Tablets, developed by an Italian company, have become a substitute for aspirin for patients who are intolerant to it [1] - According to the MoShang Pharmaceutical Database, the total hospital sales of Indobufene Tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to exceed 1.9 billion in 2024, with a year-on-year increase of 37.47%, and over 1.1 billion in the first half of 2025, with a year-on-year increase of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]

Core Viewpoint - Stone Four Pharmaceutical Group has seen a nearly 3% increase in stock price following the announcement of obtaining production registration for Indobufene tablets from the National Medical Products Administration of China, indicating a significant development in their product pipeline [1] Company Summary - Stone Four Pharmaceutical Group's stock rose by 2.68% to HKD 3.06, with a trading volume of HKD 16.01 million [1] - The company has received approval for Indobufene tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Product Summary - Indobufene tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also prevent thrombosis during hemodialysis [1] - Developed by an Italian company, Indobufene has become a substitute for aspirin in patients who are intolerant to it [1] Market Summary - According to the MoSheng Pharmaceutical Database, the total hospital sales of Indobufene tablets exceeded 1 billion in 2022, showing a year-on-year growth over the past three years [1] - Sales are projected to surpass 1.9 billion in 2024, reflecting a year-on-year increase of 37.47%, and exceed 1.1 billion in the first half of 2025, with a year-on-year growth of 28.07% [1] - The high sales figures have attracted attention from numerous pharmaceutical companies, intensifying market competition [1]

Core Viewpoint - The company Shijiazhuang Fourth Pharmaceutical Group has obtained the production registration approval from the National Medical Products Administration of China for Indobufene Tablets (0.2g), classified as a Class 3 chemical drug, which is considered equivalent to passing the consistency evaluation [1] Group 1 - Indobufene Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis, and can also be used to prevent thrombosis during hemodialysis [1]

Core Viewpoint - The company has obtained the production registration approval for Indobufen Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufen Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]